Clinical Trials Logo

Filter by:
NCT ID: NCT00925327 Not yet recruiting - Clinical trials for Progressive Keratoconus

Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking for Compassionate Treatment in Pediatric Patients With Progressive Keratoconus

CXL
Start date: n/a
Phase: Phase 2
Study type: Interventional

This is a compassionate treatment protocol for the use of the UV-X system for corneal collagen cross-linking (CXL) in eyes with progressive keratoconus in patients who have conditions that limit their capacity to comply with the cross-linking treatment procedures required by ongoing clinical trials.

NCT ID: NCT00924014 Not yet recruiting - Heart Failure Clinical Trials

Comparing the Effects of Conivaptan and Diuretics on Plasma Neurohormones and Renal Blood Flow in Patients With Chronic Congestive Heart Failure

Start date: July 2009
Phase: N/A
Study type: Interventional

The purpose of the study is to compare the effects of conivaptan and diuretics on renal blood flow and neurohormones.

NCT ID: NCT00916292 Not yet recruiting - Clinical trials for Diabetic Foot Ulcers

Safety Study of Topical Human FGF-1 for Wound Healing

Start date: November 2012
Phase: Phase 1
Study type: Interventional

The purpose of the study is to see if FGF-1 is safe when applied topically to the surface of a wound.

NCT ID: NCT00910884 Not yet recruiting - Breast Cancer Clinical Trials

Plant Extracted Natural Compounds Impact on Stage IV Breast Cancer Survival Time and Remission.

Start date: September 2020
Phase:
Study type: Observational

RATIONALE: Plant extracted natural compounds, in an adjunct therapy position, slow the growth and reproduction of Stage IV Breast Cancer tumor cells. May help eradicate different types of cancers. PURPOSE: The purpose of this randomized Phase I trial is to first IDENTIFY, through laboratory analysis and validating cellular biochemical pathways, and HELP CONTROL, using natural plant extracted compounds, G.R.A.S. (Generally Accepted As Safe), compounds, the reproduction, growth progress and metastasis of Stage IV Breast Cancer cells. The therapy position is adjunct to conventional therapies and in "one-off" trials have been excitingly effective for long-term survival. Novel use of bioactive GRAS compounds to augment and enhance conventional cancer therapies and as stand-alone parallel therapies.

NCT ID: NCT00909064 Not yet recruiting - Clinical trials for Total Knee Replacement

The Effects of Arixtra on Wound Drainage Following Total Joint Arthroplasty

Start date: June 2009
Phase: Phase 4
Study type: Interventional

The investigators hypothesize that Arixtra patients will be less likely to experience wound infection than patients who have received low-molecular weight heparin, coumadin or aspirin with mechanical compression.

NCT ID: NCT00908440 Not yet recruiting - Clinical trials for Posttraumatic Stress Disorder

Decision Aid in Veterans With Posttraumatic Stress Disorder

Start date: June 2009
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the effects of a decision aid on veterans with posttraumatic stress disorder (PTSD) presenting for care. The investigators' primary hypothesis is that patients assigned to use the decision aid will demonstrate improved quality of decisions regarding PTSD treatment relative to patients assigned to usual care. Improved decision quality will be examined by assessing patient's knowledge of treatments, evaluation of the risk and benefits, ability to arrive at a decision, and certainty about that decision. The investigators' secondary hypothesis is that patients assigned to the decision aid will be more satisfied with their care and more compliant with their care compared to patients assigned to receive usual care. The investigators will also determine whether patients assigned to the decision aid, relative to patients assigned to usual care, are more likely to receive evidence-based treatments for PTSD and experience reductions in PTSD symptoms.

NCT ID: NCT00907959 Not yet recruiting - Clinical trials for Metastatic Breast Cancer

A Clinical Trial Assessing Safety and Efficacy of BZL101 for Metastatic Breast Cancer

Start date: January 2012
Phase: Phase 2
Study type: Interventional

The investigators' proposed phase 2 clinical trial will be an open-label, non-randomized study among 80 women with metastatic breast cancer. The study treatment period will be up to twelve months and enrollment will be open at 10-15 clinical sites in the United States. In this Phase 2 trial, 40 participants with hormone receptor positive tumors and 40 with hormone receptor negative tumors will be enrolled and treated with BZL101 20 grams/day (10 grams BID). Hormone receptor positive will be defined as estrogen receptor (ER)+ and progesterone receptor (PR)+, ER+ and PR-, or ER- and PR+. Hormone receptor negative will be defined as ER- and PR-.

NCT ID: NCT00906516 Not yet recruiting - Brain Tumors Clinical Trials

Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme

Start date: May 2009
Phase: Phase 2
Study type: Interventional

Bradmer Pharmaceuticals, Inc. (Bradmer) is requesting approval to study the safety of Neuradiab® when combined with Bevacizumab (Avastin) therapy given at a minimum of 30 days after Neuradiab administration in patients with a first or second recurrence of glioblastoma multiforme (GBM), in an attempt to manage life threatening recurrence of Grade IV malignant glioma.

NCT ID: NCT00889655 Not yet recruiting - Colonoscopy Clinical Trials

A Trial Comparing Bowel Preparation and Patient Tolerability of Miralax Versus Golytely

Start date: May 2009
Phase: Phase 4
Study type: Interventional

Prior to colonoscopies, the colon is cleansed using a laxative. Golytely is approved by the FDA for this purpose. Another laxative, called MiraLax, is approved by the FDA to relieve constipation, but it is not approved specifically for preparation for a colonoscopy. Nonetheless, it is commonly used in clinical practice for this purpose, just as is Golytely. The purpose of this study is to compare Golytely and MiraLax in two ways: to see whether one is better tolerated by patients than the other and to see whether one more effectively cleanses the bowel than the other. The investigators' hypothesis is that these 2 bowel preparation methods are equally effective in bowel cleansing, but that patients prefer Miralax to Golytely.

NCT ID: NCT00888199 Not yet recruiting - Amputation Clinical Trials

Clinical Trial of Tensegrity Prosthetics K3 Promoter Foot Prosthesis

Start date: January 2010
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this clinical trial is to determine if the experimental Tensegrity prosthetic foot offers a reduction of the amount of oxygen used while walking, if stability is improved over current prosthetic feet, and whether the experimental device actually increases activity in amputees.